Neutropenia is one of the most severe hematologic toxicities of cancer chemotherapy and often limits the doses of chemotherapy tolerated by the patients. It is a condition that results in a low neutrophil count in the blood, thus rendering the patient susceptible to infections from pathogens, ultimately leading to fever – in the case known as Chemotherapy-Induced Febrile Neutropenia (CIFN).
Febrile neutropenia one of the most common and adverse complications of chemotherapy, which in addition to reduced immunity, also delays the course of treatments, leads to early termination of the doses and compromises with the potential of curing the patient.
Rolontis (Spectrum Pharmaceuticals, Inc.), Fulphila (Mylan), Udenyca (Coherus BioSciences), Mosedipimod (Enzychem Lifesciences ), Pelmeg (CINFA), Ziextenzo (Sandoz), Myelo001 (Myelo Therapeutics GmbH), ALRN-6924 (Aileron Therapeutics) along with Neulasta #biosimilars including MYL-1401H (Mylan), CHS-1701 (Coherus BioSciences), B12109 (CINFA) and LA-EP2006 (Sandoz) are anticipated to impact Chemotherapy-Induced Febrile Neutropenia market positively in the coming years.
For more details visit:
https://www.delveinsight.com/blog/chemotherapy-induced-febrile-neutropenia-market/